About the Company
Abeona Therapeutics Inc. (NASDAQ: ABEO) is a clinical-stage biopharmaceutical company focused on developing novel therapies for life-threatening rare genetic diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases.
Advancing treatments for rare diseases…Working together to find a cure.
cureA rare disease is one that affects fewer than 200,000 people in the United States. There are nearly 7,000 rare diseases, which may involve chronic illness, disability, and often, premature death. More than 25 million Americans and 30 million Europeans have one.
While rare diseases can affect any age group, about 50% of people affected are children (15 million); and rare diseases account for 35% of deaths in the first year of life.
These rare diseases are often poorly diagnosed, very complex, and have no treatment or not very effective treatment—over 95% of rare diseases do not have a single FDA or EMA approved drug treatment. However, most rare diseases are often caused by changes in genes—80% are genetic in origin and can present at any stage of life.
We believe emerging insights in genetics and advances in biotechnology, as well as new approaches and collaboration between researchers, industry, regulators and patient groups, provide significant opportunities to develop breakthrough treatments for rare diseases.
Investor Conference Call to be held Monday, November 20th at 10:00 am ET Global enrollment continues in ABO-102 trial for MPS IIIA Screening initiated in ABO-101 Phase 1/2 trial for MPS IIIB Pivotal Phase 3 planning underway for EB-101...
NEW YORK and CLEVELAND, Nov. 13, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the Company’s senior management team will...
Company Opens European Subsidiary in Spain to Support Global Clinical Development Nine subjects at global clinical sites enrolled to date with more than 2,000 days cumulative follow up assessed NEW YORK and CLEVELAND, Nov. 09, 2017 (GLOBE NEWSWIRE) — Abeona...
Abeona Announces Closing of $92 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
NEW YORK and CLEVELAND, Oct. 19, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, today announced the closing of its underwritten public offering...